FibroGen, Inc.
FGEN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $2 | $37 | $33 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $2 | $37 | $32 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -36.7% | -66.7% | -40.2% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 47.5% | 91.5% | 85.6% | -90.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -480.8% | -652.1% | -201% | -141.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -160.6% | -607.3% | -208.7% | -123.3% |
| EPS Diluted | -0.48 | -2.92 | -3.15 | -3.15 |
| % Growth | 83.6% | 7.3% | 0% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |